<DOC>
	<DOC>NCT02929615</DOC>
	<brief_summary>The purpose of the study is to research the standard and individualized treatment model for relapse and refractory lymphatic system malignant tumors.</brief_summary>
	<brief_title>Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors</brief_title>
	<detailed_description />
	<criteria>1. Patients with relapse and refractory lymphoma and multiple myeloma. 2. At least 1 measurable lesions and its size≥15mm. 3. Patients ≤65 years，no limitations for both gender. 4. ECOG score is 01. 5. Life expectancy≥3 months. 6. LVEF≥ 55%; Peripheral blood: WBC ≥ 3.5×10(9)/L,neutrophil ≥1.5×10(9)/L, PLT≥75×109/L，Hb≥90g/L; Renal function: Cr≤2.0×UNL; Liver function: BIL≤2.0×UNL，ALT/AST≤2.5×UNL; 7. Written informed consent are acquired. 1. Previously received stem cell transplantation. 2. Women with pregnant, lactating or not to take contraceptive measures. 3. Severe acute infection or suppurative and chronic infection that wound not healing. 4. Severe heart failure. 5. Suffering from mental disorders and poor compliance. 6. Other situations that investigators consider as contraindication for this study.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>